OpenAI-backed Nabla Bio's JAM-2 AI model designs antibodies ready for human trials, potentially revolutionizing drug ...

Based on an integrated analysis of the efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) data from dose optimization cohorts receiving IBI3003 at 120, 360, and 540 µg/kg in the Phase 1 ...

Innovent Biologics, Inc. announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma ...

Lung cancer remains the deadliest malignancy worldwide, and non-small cell lung cancer (NSCLC) accounts for roughly 85 ...

Pregnancy demands one of the most remarkable immunological balancing acts in human biology. The developing fetus carries genetic material from both parents, making it, from the immune system’s p ...

Peanut allergy is one of the most serious food allergies and can lead to sudden, life-threatening reactions. Researchers from ...

Dublin, Sept. 21, 2026 (GLOBE NEWSWIRE) -- "Monoclonal Antibody Collaboration and Licensing Deals 2019-2026" has been added to ResearchAndMarkets.com's offering.This report provides a comprehensive ...

FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases HONG KONG and SHANGHAI and ...

ASC50 is an in-house discovered and developed oral small molecule inhibitor targeting IL-17A, an important biologically and commercially validated target for multiple autoimmune and inflammatory ...

Envisagenics’ AI-powered SpliceCore® platform opens up alternative RNA splicing – one of the last largely untapped sources of tumor-specific ...

Antibody solubility differences from 7- to 200-fold are tied to excipients’ molecular specificity and interaction complexity.

Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced today that the U.S. Patent and Trademark ...